Financial Results - Standalone (Rs. in Lakhs)

Income Statement:

  • Revenue from Operations: ₹593.89 (6 months ended 30/09/2026) vs ₹452.50 (6 months ended 31/03/2026) vs ₹399.15 (6 months ended 30/09/2025)
  • Other Income: ₹16.57
  • Total Income: ₹610.46
  • Total Expenses: ₹587.33
  • Profit before Tax: ₹23.13 vs loss of ₹42.51 in previous half-year
  • Tax Expenses: Current Tax ₹1.64, Deferred Tax ₹1.72
  • Profit after Tax: ₹19.76 vs loss of ₹45.95 in previous half-year
  • Earnings Per Share (Face Value ₹10): Basic ₹0.23, Diluted ₹0.23

Balance Sheet (Standalone as at 30th September, 2026):

  • Share Capital: ₹871.20
  • Reserves and Surplus: (₹32.97)
  • Long-term Borrowings: ₹418.08
  • Short-term Borrowings: ₹156.85
  • Total Equity and Liabilities: ₹1,512.11
  • Property, Plant and Equipment: ₹784.62
  • Non-current Investments: ₹204.11
  • Inventories: ₹229.87
  • Total Assets: ₹1,512.11

Cash Flow Statement (Standalone):

  • Net Cash from Operating Activities: ₹139.66
  • Net Cash used in Investing Activities: (₹43.12)
  • Net Cash used in Financing Activities: (₹92.10)
  • Net Increase in Cash: ₹4.44
  • Closing Cash Balance: ₹7.89

Financial Results - Consolidated (Rs. in Lakhs)

Income Statement:

  • Revenue from Operations: ₹730.76
  • Other Income: ₹21.58
  • Total Income: ₹752.34
  • Total Expenses: ₹728.77
  • Profit before Tax: ₹40.37
  • Tax Expenses: Current Tax ₹1.75, Deferred Tax ₹1.38
  • Profit after Tax: ₹20.44
  • Earnings Per Share: Basic ₹0.23, Diluted ₹0.23

Balance Sheet (Consolidated as at 30th September, 2026):

  • Share Capital: ₹871.20
  • Reserves and Surplus: (₹40.48)
  • Long-term Borrowings: ₹459.51
  • Total Equity and Liabilities: ₹1,580.44
  • Property, Plant and Equipment: ₹878.04
  • Total Assets: ₹1,580.44

Key Notes and Disclosures

1. The financial results were reviewed by the audit committee and approved by the board on November 06, 2026.

2. The results were reviewed by statutory auditors M G H V S & ASSOCIATES who issued an unmodified review report.

3. EPS computed in accordance with Accounting Standard AS-20.

4. Business segments: Pharma Products (Revenue: ₹216.22 lakhs, Assets: ₹136.72 lakhs) and Freeze-dried Products (Revenue: ₹377.67 lakhs, Assets: ₹1,049.10 lakhs).

5. The company fully utilized IPO proceeds of ₹622.20 lakhs as of March 31, 2026, with no further utilization during H1 FY27. Breakdown:

  • Plant and Machinery & construction: ₹359.00
  • Brand visibility: ₹50.00
  • General corporate purposes: ₹151.87
  • Issue Expenses: ₹61.33

6. The consolidation includes wholly owned subsidiary HSDL INNOVATIVES PRIVATE LIMITED, acquired on March 25, 2026.

7. Inventory valued at lower of cost or net realizable value using FIFO method.

8. Previous year figures have been regrouped/reclassified where necessary.